TargeGen
A vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target.
Launch date
Employees
Market cap
-
Enterprise valuation
€509m (Public information from Jun 2010)
San Diego California (HQ)
Authorizing premium user...